SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia

Background Acute myeloid leukemia (AML) is a disease characterized by the proliferation of abnormal cells originating from blood stem cells. Understanding the pathogenesis and progression of AML, as well as identifying molecular markers for early diagnosis and prognosis assessment, is of paramount i...

Full description

Saved in:
Bibliographic Details
Main Authors: MengMeng Zhang, YuanYuan Tan, ZhiBin Xie, Meng Wang, JiaJia Li
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Hematology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2024.2420301
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846126640325722112
author MengMeng Zhang
YuanYuan Tan
ZhiBin Xie
Meng Wang
JiaJia Li
author_facet MengMeng Zhang
YuanYuan Tan
ZhiBin Xie
Meng Wang
JiaJia Li
author_sort MengMeng Zhang
collection DOAJ
description Background Acute myeloid leukemia (AML) is a disease characterized by the proliferation of abnormal cells originating from blood stem cells. Understanding the pathogenesis and progression of AML, as well as identifying molecular markers for early diagnosis and prognosis assessment, is of paramount importance.Methods The AML dataset was obtained from the Cancer Genome Atlas (TCGA), while the normal sample dataset was derived from the Genotype-Tissue Expression(GTEx) dataset. Furthermore, the association between SRSF12 expression and drug response was assessed using the Cancer Therapeutic Response Portal (CTRP) database to evaluate its potential therapeutic value. Finally, SRSF12 expression in AML cells was measured using quantitative real-time PCR (qRT-PCR).Result The difference in SRSF12 expression between 13 types of tumors and normal tissue samples was found to be statistically significant (P < 0.05). SRSF12 exhibited predominantly high expression in AML, indicating its potential as a diagnostic and prognostic marker for AML patients. High expression of SRSF12, along with age and cytogenetic risk, emerged as independent predictors of favorable prognosis in AML patients (P < 0.05). PCR demonstrated a significant increase in SRSF12 expression in AML patients.Conclusion Overall, our findings suggest that the high expression of SRSF12 in AML patients is a poor prognostic factor, which may provide a new option for the diagnosis, and targeted therapy of AML.
format Article
id doaj-art-3b76e5b9741c47b4920ce684293d1da2
institution Kabale University
issn 1607-8454
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Hematology
spelling doaj-art-3b76e5b9741c47b4920ce684293d1da22024-12-12T15:08:53ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2420301SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemiaMengMeng Zhang0YuanYuan Tan1ZhiBin Xie2Meng Wang3JiaJia Li4Department of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233003, Anhui Province, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233003, Anhui Province, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233003, Anhui Province, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233003, Anhui Province, People’s Republic of ChinaDepartment of Hematology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233003, Anhui Province, People’s Republic of ChinaBackground Acute myeloid leukemia (AML) is a disease characterized by the proliferation of abnormal cells originating from blood stem cells. Understanding the pathogenesis and progression of AML, as well as identifying molecular markers for early diagnosis and prognosis assessment, is of paramount importance.Methods The AML dataset was obtained from the Cancer Genome Atlas (TCGA), while the normal sample dataset was derived from the Genotype-Tissue Expression(GTEx) dataset. Furthermore, the association between SRSF12 expression and drug response was assessed using the Cancer Therapeutic Response Portal (CTRP) database to evaluate its potential therapeutic value. Finally, SRSF12 expression in AML cells was measured using quantitative real-time PCR (qRT-PCR).Result The difference in SRSF12 expression between 13 types of tumors and normal tissue samples was found to be statistically significant (P < 0.05). SRSF12 exhibited predominantly high expression in AML, indicating its potential as a diagnostic and prognostic marker for AML patients. High expression of SRSF12, along with age and cytogenetic risk, emerged as independent predictors of favorable prognosis in AML patients (P < 0.05). PCR demonstrated a significant increase in SRSF12 expression in AML patients.Conclusion Overall, our findings suggest that the high expression of SRSF12 in AML patients is a poor prognostic factor, which may provide a new option for the diagnosis, and targeted therapy of AML.https://www.tandfonline.com/doi/10.1080/16078454.2024.2420301SRSF12acute myeloid leukemiaprognosisimmune cellsbiomarker
spellingShingle MengMeng Zhang
YuanYuan Tan
ZhiBin Xie
Meng Wang
JiaJia Li
SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia
Hematology
SRSF12
acute myeloid leukemia
prognosis
immune cells
biomarker
title SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia
title_full SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia
title_fullStr SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia
title_full_unstemmed SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia
title_short SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia
title_sort srsf12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia
topic SRSF12
acute myeloid leukemia
prognosis
immune cells
biomarker
url https://www.tandfonline.com/doi/10.1080/16078454.2024.2420301
work_keys_str_mv AT mengmengzhang srsf12isaprognosticbiomarkerinvolvedinimmuneinfiltrationinacutemyeloidleukemia
AT yuanyuantan srsf12isaprognosticbiomarkerinvolvedinimmuneinfiltrationinacutemyeloidleukemia
AT zhibinxie srsf12isaprognosticbiomarkerinvolvedinimmuneinfiltrationinacutemyeloidleukemia
AT mengwang srsf12isaprognosticbiomarkerinvolvedinimmuneinfiltrationinacutemyeloidleukemia
AT jiajiali srsf12isaprognosticbiomarkerinvolvedinimmuneinfiltrationinacutemyeloidleukemia